CAS 1191237-69-0 API Active Pharmaceutical Ingredient For FIP Cats Treatments

Product Description

GS441524 99% Purity For FIPV Treatments Of Your Cats Cas 1191237-69-0

Additional test

What is  GS441524 ?

Gs-441524 is the second targeted antiviral agent after GC376 for feline infectious peritonitis (FIP). Gs-441524 is a small molecule nucleotide analogue provided by GileadSciences(NO.1 in the world antiviral field) to PerdersenNCjiaoshou2 and its abdominal transabdominal research topic at UCDavis (NO.1 in the world Chemicalbook veterinary medicine). It is a reverse transcriptase inhibitor that can inhibit the replication of feline ventral virus (FIP) and is a prerequisite molecule for the synthesis of nucleoside triphosphate with pharmacological activity .

Gs-441524 is a small molecule, known as a competitive nucleoside triphosphate inhibitor, showing strong antiviral activity against many RNA viruses. Can inhibit the replication of several different types of RNA viruses, such as zoonotic severe Chemicalbook acute respiratory syndrome (SARS) coronavirus, Middle East respiratory syndrome virus, Ebola virus, Lassa fever virus, Junin virus and respiratory syncytial virus, while showing low cytotoxicity in a wide range of cell lines .

Feline infectious peritonitis (FIP) is a devastating and almost always fatal feline disease resulting from a mutation of the common feline coronavirus (FECV), which infects 40-80% of cats worldwide. Gs-441524, also known as GS-5734, is an effective inhibitor of feline infectious peritonitis (FIP) virus. Gs-441524 showed strong inhibition against feline infectious peritonitis (FIP) virus Chemicalbook. Gs-441524 is a molecular precursor of a pharmacologically active nucleoside triphosphate molecule. These analogues can be used as surrogate substrates and RNA chain terminators for viral RNA-dependent RNA polymerases. Gs-441524 was non-toxic in feline cells with concentrations up to 100, and effectively inhibited FIPV replication in CRFK cell culture and natural infection in cat peritoneal macrophages with concentrations as low as 1

The emergence of exotic diseases such as Ebola and SARS(Severe acute respiratory syndrome) has led to intensive research into new drug treatments, which have indirectly benefited cats. Feline infectious peritonitis (FIP) is one of the chronic viral infections in cats, similar to humans, that is estimated to kill up to 1.4% of cats worldwide. The infectious agent is a mutated coronavirus (FIPV) that is notoriously difficult to control: parental-intestinal coronavirus is present in almost all felines and shelters, and is shed by 60% or more of pet cats from multi-cat families, 1 and vaccines are ineffective.

The most promising treatment for emerging human viruses is 'GS-5734', a small molecule antiviral that targets specific proteins involved in RNA virus replication. In studies, it has been shown to be effective in preventing Ebola virus in rhesus monkeys and inhibiting coronavirus in tissue cultures and mouse models of infection. It was these findings that caught the attention of veterinary researchers in the US, led by Professor Niels Pedersen of the University of California, Davis. Their own preliminary studies involving experimental FIP showed that the less chemically active 'GS-441524'(the parent nucleoside of GS-5734) was highly effective, opening the way for field trials in cats with naturally occurring FIP. The results are compelling and published in the February 13, 2019 issue of the Journal of Feline and Surgery (JFMS)*

Thirty-one cats, ages 3 to 73 months, participated in the study, and 26 completed the planned 12 weeks or longer of treatment; The rest died of serious illness or were euthanized. For these 26 cats, the clinical response was significant: fever usually subsided within 12-36 hours, with significant improvement in appetite, activity levels, and weight gain. In cats with the more common exudative or "wet" form of FIP, the peritoneal effusion disappears rapidly, beginning about 10-14 days after initiation of treatment. Encouragingly, and somewhat unexpectedly, cats with non-influenza (" dry ")FIP and older cats also responded to GS-441524 as well as cats with epidemic FIP and kittens. The GS-441524's security is also impressive.

Currently, 24 of the 26 cats remain healthy, with one dying of FIP disease and the other from an unrelated heart condition. Eighteen of the cats received one round of treatment; The remaining eight patients had relapsed, but these patients were successfully treated with further (two, third round) treatment at higher doses.

Previously, the outlook for FIP cats was bleak. In a groundbreaking review article on FIP published in JFMS a decade ago, Prof Pedersen stated: "Despite such claims, no treatment has been effective in treating felines with FIP." Cats that develop FIP inevitably die of illness within days, weeks or months.1 Now, as he nears the end of his career, Professor Pedersen is rather optimistic: 'FIP has been my fascination for the last 50 years and I have been fortunate to identify safe and effective antiviral drugs at the end of my career. We now know that small molecules that target specific steps of RNA virus replication can safely cure various forms of FIP. However, he warned: 'It must be stressed that the field tests we reported were for proof-of-concept purposes and the results cannot be immediately translated into commercial products. Unfortunately, these initial trials offer real hope that increases, not decreases, owners' desperation to find these new drugs on the black market. Eventful as these findings may be, there's still more to discover about FIP. I would like to thank all the people, organizations and owners who have assisted me in this half century of research and have left the remaining questions and related findings with my FIP researchers. Owners are desperate to find these new drugs on the black market. Eventful as these findings may be, there's still more to discover about FIP. I would like to thank all the people, organizations and owners who have assisted me in this half century of research and have left the remaining questions and related findings with my FIP researchers. Owners are desperate to find these new drugs on the black market. Eventful as these findings may be, there's still more to discover about FIP. I would like to thank all the people, organizations and owners who have assisted me in this half century of research and have left the remaining questions and related findings with my FIP researchers.